Beranda › Sistem Imun dan Gangguan › Massachusetts › Boston
Uji klinis Sistem Imun dan Gangguan di Boston, MA
10 studi untuk Sistem Imun dan Gangguan mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
- Massachusetts General Hospital, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Menerima pesertaStudi observasional
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
- Massachusetts General Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Menerima pesertaFase 1/2
- Brigham and Women's Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
Uji klinis Sistem Imun dan Gangguan di kota lain
- Washington, DC13 studi
- New York City, NY12 studi
- Philadelphia, PA10 studi
- Portland, OR9 studi
- Atlanta, GA9 studi
- Houston, TX9 studi
- Chicago, IL8 studi
- Los Angeles, CA8 studi
- Cleveland, OH8 studi
- Seattle, WA6 studi
- Milwaukee, WI6 studi
- Cedar Rapids, IA6 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Paru62 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.